|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
TK1, TRIP13 and OCT4 were found to exhibit concurrent higher expression levels in HCC tumors than in APTs.
|
31848930 |
2020 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
HLF is a novel oncofetal protein which is reactivated in HCC by SOX2 and OCT4.
|
31118247 |
2019 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
The ZnAs@SiO<sub>2</sub> NPs also inhibited tumor spheroid formation <i>in vitro</i> and tumor initiation <i>in vivo</i> and induced significant changes in the expression of stemness markers (CD133, Sox-2, and Oct-4) and EMT markers (E-cadherin, Vimentin, and Slug) both <i>in vitro</i> and <i>in vivo.</i> These effects of ZnAs@SiO<sub>2</sub> that correlated with prognosis of HCC were mediated by the SHP-1/JAK2/STAT3 signaling.
|
31285768 |
2019 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Both HOXA11-AS silencing and HOXA11 overexpression suppressed the self-renewal, proliferation, migration, and tumorigenicity of HCC stem cells in vivo, as evidenced by the decreased expression of cancer stem cell surface markers (CD133 and CD44) and stemness-related transcription factors (Nanog, Sox2, and Oct4).
|
31757938 |
2019 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype.
|
30959553 |
2019 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
Furthermore, the loss of Oct4 inhibited HCC cell malignant progression accompanied by downregulated expression of the survivin/signal transducer and activator of transcription 3 (STAT3) pathway.
|
29901157 |
2018 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
Oct3/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells.
|
30250594 |
2018 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
We demonstrated that marked upregulation of [Formula: see text]-catenin and its downstream targets effectively enhanced hepatosphere formation, with an associated induction of CD133, OCT4 and Sox2 expression and also caused an significant enhancement of HCC proliferation.
|
29792038 |
2018 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Combination of NANOG and OCT4 expression was indicated as valuable prognostic signature for HCC recurrence prediction (P < 0.0011).
|
30506712 |
2018 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
The present findings provide novel mechanistic insight into an important role of Oct4 in HCC.
|
28454439 |
2017 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
We report that Oct4, Klf4, Sox2 and c-myc expression positively associated with AFP(+)/HBV(+) hepatocellular carcinoma(HCC) tissues, and the expression of the stemness markers CD44, CD133 and EpCAM was significantly higher in AFP(+)/HBV(+) HCC tissues compared to normal liver tissues or AFP (-)/HBV(-) HCC tissues.
|
27925189 |
2017 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
These findings suggest that HCV core protein regulates OCT4 expression and promotes cell cycle progression in hepatocellular carcinoma providing new insight into the mechanism of hepatocarcinogenesis by HCV infection.
|
27121765 |
2016 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
Meanwhile, OCT4 has relationship with poor prognosis in a lot of solid tumors, such as hepatocellular carcinoma, gastric cancer, and esophageal cancer.
|
26152287 |
2015 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
The concurrent expression of OCT4/NANOG/IGFIR was mostly confined to hepatitis B virus (HBV)-related HCC (HBV-HCC) and was significantly correlated with early tumor recurrence.
|
25564572 |
2015 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Taken together, our finding adds a new layer of post-transcriptional regulation of OCT4 and sheds new light on the treatment of human HCC.
|
23615404 |
2013 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
We quantified levels of p28(GANK) (Gankyrin), OV6, and Oct4 in 130 human HCC samples using immunohistochemistry.
|
22387393 |
2012 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by real time PCR (n = 53).
|
22439694 |
2012 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Finally, we show that knockdown of Sox2 and Oct3/4 gene expression in HCC cells can reduce carboplatin-mediated increases in sphere formation and increase cellular sensitivity to chemotherapy.
|
22732500 |
2012 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
Our previous study showed that SOX2 and OCT4 were negative predictors for hepatocellular carcinoma (HCC).
|
22429493 |
2012 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy.
|
21376027 |
2011 |
|
POU5F1P3
|
Liver carcinoma
|
0.100 |
Biomarker |
BEFREE |
Silencing of Oct4 and TCF3 in HCC cell line HepG2 revealed that there were complicated relationships among Oct4, wnt/β-catenin family and TGF-β family genes.
|
20549546 |
2010 |